Patient demographics and baseline disease characteristics
| Characteristic . | Value (range) . |
|---|---|
| All patients, n | 22 |
| Median age, y (range) | 60 (47-77) |
| Male, n (%) | 13 (59) |
| Histologic subtype, n (%) | |
| FL | 10 (45) |
| DLBCL | 3 (14) |
| Other aggressive histology (MCL + transformed MZL) | 2 (9) |
| Small lymphocytic lymphoma | 2 (9) |
| CLL | 5 (23) |
| No. of prior therapies, median (range) | 4 (1–7) |
| Received prior rituximab-containing regimen, n | 19 |
| No. of rituximab-containing regimens, median (range) | 2 (1–4) |
| No. of rituximab-refractory patients (n = 19), n (%) | 13 (68) |
| NHL patients, n | 17 |
| Received prior anthracycline, n (%) | 11 (65) |
| Received prior ASCT | 3 (18) |
| Clinical stage (Ann Arbor), n (%) | |
| I/II | 2 (12) |
| III/IV | 15 (88) |
| Follicular lymphoma prognostic index (n = 10), n (%) | |
| Low risk (0-1 risk factors) | 3 (30) |
| Intermediate risk (2 risk factors) | 2 (20) |
| High risk (3-5 risk factors) | 4 (40) |
| Unknown | 1 (10) |
| CLL patients, n | 5 |
| Refractory to fludarabine | 5 (100) |
| Rai stage, n (%) | |
| Intermediate risk (I and II) | 4 (80) |
| High risk (III and IV) | 1 (20) |
| Characteristic . | Value (range) . |
|---|---|
| All patients, n | 22 |
| Median age, y (range) | 60 (47-77) |
| Male, n (%) | 13 (59) |
| Histologic subtype, n (%) | |
| FL | 10 (45) |
| DLBCL | 3 (14) |
| Other aggressive histology (MCL + transformed MZL) | 2 (9) |
| Small lymphocytic lymphoma | 2 (9) |
| CLL | 5 (23) |
| No. of prior therapies, median (range) | 4 (1–7) |
| Received prior rituximab-containing regimen, n | 19 |
| No. of rituximab-containing regimens, median (range) | 2 (1–4) |
| No. of rituximab-refractory patients (n = 19), n (%) | 13 (68) |
| NHL patients, n | 17 |
| Received prior anthracycline, n (%) | 11 (65) |
| Received prior ASCT | 3 (18) |
| Clinical stage (Ann Arbor), n (%) | |
| I/II | 2 (12) |
| III/IV | 15 (88) |
| Follicular lymphoma prognostic index (n = 10), n (%) | |
| Low risk (0-1 risk factors) | 3 (30) |
| Intermediate risk (2 risk factors) | 2 (20) |
| High risk (3-5 risk factors) | 4 (40) |
| Unknown | 1 (10) |
| CLL patients, n | 5 |
| Refractory to fludarabine | 5 (100) |
| Rai stage, n (%) | |
| Intermediate risk (I and II) | 4 (80) |
| High risk (III and IV) | 1 (20) |
MCL indicates mantle cell lymphoma; MZL, marginal zone lymphoma; and ASCT, autologous stem cell transplantation.